ea0047oc8 | Spotlight on Neuroendocrine tumours | Theranostics2016
Strosberg Jonathan
, Wolin E
, Chasen B
, Kulke M
, Bushnell D
, Caplin M
, Baum R P
, Kunz P
, Hobday T
, Hendifar A
, Oberg K
, Lopera Sierra M
, Kwekkeboom D
, Ruszniewski P
, Krenning E
Background: Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4...